CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
Status:
Recruiting
Trial end date:
2022-04-15
Target enrollment:
Participant gender:
Summary
This trial will test the hypothesis that the administration of CF101, a novel
anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve
signs and symptoms of the disease. CF101 effect will be in comparison to apremilast in this
study population